Picture EBD Group BioPharm America 2020 Digital Event BEU2020 650x81
Document › Details

Alligator Bioscience AB. (1/18/18). "Press Release: Alligator Bioscience Appoints New VP Business Development". Lund.

Organisations Organisation Alligator Bioscience AB (Nasdaq Stockholm: ATORX)
  Group Alligator Bioscience (Group)
  Organisation 2 AstraZeneca (Group)
Products Product mitazalimab (ADC-1013)
  Product 2 ADC-1015 (Alligator Bioscience)
Persons Person Balendran, Anu (Alligator Bioscience 201805– VP Business Development before AstraZeneca External Innovation Director)
  Person 2 Norlén, Per (Alligator Bioscience 201606 CEO)

Alligator Bioscience (Nasdaq Stockholm: ATORX), a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, announced today the appointment of Anu Balendran, PhD, as Vice President Business Development.

Dr Balendran will be responsible for leading Alligator’s preclinical projects towards out-licensing. He has a PhD in Biochemistry and will join Alligator from his current role as External Innovation Director, AstraZeneca. He will assume his new role on 1 May 2018.

This appointment follows those of Charlotte A Russell, MD, PhD, as Chief Medical Officer and Peter Ellmark, PhD, Associate Professor, as Vice President Discovery, in December 2017, as Alligator prepares a number of drug candidates for clinical studies, partnerships and licensing deals.

“With three preclinical projects approaching clinical development and our business model to out-license projects after proof-of-concept in cancer patients, we are very pleased to make this important appointment to the management team. We look forward to welcoming Anu to Alligator. He brings extensive international experience in drug licensing and collaboration, complementing the growing team at Alligator”, said Per Norlén, CEO at Alligator Bioscience.

For further information:

Cecilia Hofvander, Director Investor Relations & Communications
Phone +46 46 286 44 95

The information was submitted for publication, through the agency of the contact person set out above, at 08:30 a.m. CET on 18 January 2018.

About Alligator Bioscience

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes four lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527). ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 50 employees. For more information, please visit

Record changed: 2018-01-24


Picture EBD Group BIO-Europe 2020 Digital Event BEU2020 650x81

More documents for Alligator Bioscience (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture Kentro Design Corporate and Web Design Berlin 650x65px

» top